Engineering the optimal immune synapse through synthetic design to surpass the endogenous immune response
28 Apr 2026
Bi/Multispecifics
- Why is reliance on the endogenous immune recognition system (TCE + MHC + antigen) insufficient for effective immune responses in many tumor settings?
- What are the barriers preventing next-generation approaches that directly engage the T cell receptor complex from achieving sufficient efficacy or avoiding excessive toxicity?
- How can the design and testing of multi-specific engagers be optimized to incorporate co-stimulatory capacity in next-generation T cell engagers (TCEs)?
- What challenges arise from co-stimulation, such as hyper-toxicity due to multi-valency or inadequate monotherapy function when monovalent?
- How can the integration of signal 1, signal 2, and signal 3 at the tumor cell surface within a single molecule address the limitations of current T cell engager therapies?
Industry Expert
